AstraZeneca announced it has completed patient enrollment approximately four months ahead of plan in the Phase 3 clinical trial EUCLID studying Brilinta (ticagrelor) tablets. Part of PARTHENON, AstraZeneca’s largest clinical trial program, EUCLID has randomized more than 13,500 patients globally with peripheral artery disease (PAD); approximately 20% are patients in the United States (U.S.) from more than 300 active clinical trial sites across the country.
EUCLID is designed to evaluate the effects of ticagrelor (monotherapy) compared to clopidogrel (monotherapy) on cardiovascular (CV) events and safety in PAD patients. Ticagrelor is currently not approved for the treatment of patients with PAD.
“We are very excited to have completed enrollment in the EUCLID study ahead of schedule. This study will provide important information regarding the use of oral antiplatelet agents in peripheral artery disease,” said EUCLID study chair William Hiatt, Professor of Medicine, division of cardiology, University of Colorado School of Medicine and CPC Clinical Research. “PAD affects approximately 202 million people globally and 8.5 million people in the US. Patients living with the disease are at high risk for developing myocardial infarctions, strokes, and other health complications.”
AstraZeneca also announced that U.S. recruitment and enrollment is underway in two additional Phase 3 PARTHENON studies– SOCRATES and THEMIS. SOCRATES (Acute Stroke Or Transient IsChaemic Attack TReated with Aspirin or Ticagrelor and Patient OutcomES) will evaluate the efficacy of ticagrelor compared to aspirin in reducing major vascular events in patients with acute ischemic stroke or transient ischemic attack (TIA). Brilinta is currently not approved for the treatment of patients with ischemic stroke or TIA. THEMIS (Effect of Ticagrelor on Health Outcomes in DiabEtes Mellitus Patients Intervention Study) will evaluate the efficacy of ticagrelor versus placebo, on top of standard of care including aspirin, for the long-term prevention of major vascular events in patients with Type 2 diabetes and coronary atherosclerosis. Brilinta is not currently approved for the prevention of CV events in patients with diabetes and coronary atherosclerosis.
“Even with aspirin, more than 10% of patients who have had an acute ischemic stroke or transient ischemic attack will have a subsequent major stroke within 90 days. We strongly encourage physicians to refer appropriate patients for enrollment in the SOCRATES clinical trial, which will be investigating whether the use of ticagrelor in this patient population can help address a substantial unmet need,” said SOCRATES study co-chair Clay Johnston, director, Clinical and Translational Science Institute, associate vice chancellor of research, University of California, San Francisco (UCSF).
“Of the approximately 26 million people in the US who suffer from diabetes, over 90% have Type 2 diabetes– and nearly two-thirds of them will die from cardiovascular disease,” said THEMIS study co-chair Deepak Bhatt, executive director of interventional cardiovascular programs, Brigham and Women’s Hospital Heart and Vascular Center, and professor of medicine at Harvard Medical School. “The THEMIS study will explore the use of ticagrelor in patients with diabetes, and hopes to provide new scientific evidence to guide appropriate treatment for these high-risk patients, with all of their associated comorbidities.”
“We really value our collaborations with these top academic institutions and clinician-scientists leading the studies that may add substantially to our scientific understanding of appropriate treatment across the spectrum of atherosclerotic disease– including PAD, stroke and diabetes,” said James Ferguson, vice president, Cardiovascular Therapeutic Area, US Medical Affairs, AstraZeneca. “AstraZeneca is fully committed to broader exploration of the potential for Brilinta in these additional high-risk clinical circumstances.”
EUCLID, SOCRATES, and THEMIS each have an Independent Data Monitoring Committee, which will review the safety and efficacy of treatments in these trials. The trials will be conducted in accordance with Good Clinical Practice.
Date: March 17, 2014